NCT00867750已完成2 期
Radioembolisation (RE) With SIR-Spheres® Microspheres Versus Transarterial Chemoembolisation (TACE) in Patients With Unresectable Hepatocellular Carcinoma (HCC). A Comparative, Prospective, Randomised, Open, Pilot Study.
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 28
- 试验地点
- 2
- 主要终点
- Health-related quality of life (HRQL)
研究概览
简要总结
This study is open to patients with primary HCC who cannot be treated by potentially curative treatment modalities, such as surgical resection, liver transplantation or percutaneous ablation.
Patients that satisfy the study eligibility criteria will be randomised in a 1: 1 ratio to receive either Radioembolisation with SIR-Spheres Microspheres or the standardised Transarterial Chemoembolisation procedure.
Study Objectives
This study will evaluate and compare quality of life as well as safety and efficacy of RE or TACE in patients with unresectable HCC. Patients will be followed for a minimum of 12 months or until death wherever possible in the evaluation of the primary and secondary objectives of this study.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Male or female patients, aged ≥ 18 years
- •Unequivocal diagnosis of primary HCC (confirmed by biopsy/histology or EASL criteria)
- •Tumour characteristics as follows:
- •Not more than 5 lesions
- •If single, maximal diameter ≤ 10 cm
- •If multiple, sum of maximal diameters ≤ 15 cm
- •Lesions satellite to primary tumour of less than 1 cm in maximal diameter are not included
- •At least one quantifiable lesion on hepatic MRI
- •Preserved liver function, corresponding to Child-Pugh class ≤ B-7
- •ECOG performance status ≤ 2
- •Life expectancy ≥ 12 weeks
- •Female patients of childbearing potential must have a negative pregnancy test prior to inclusion in the trial and male and female patients must agree to use an effective contraceptive method for the duration of the trial.
- •Willing and able to provide written informed consent
排除标准
- •Patients expected to undergo surgery (resection or transplantation) within the 24-week period after randomisation.
- •Ascites, which is detectable on physical examination or clinically symptomatic (but patients having ascites discovered by imaging only should not be excluded).
- •Serum transaminases > 5 x ULN
- •Lung shunt > 20%
- •Extrahepatic disease
- •Moderate to severe portal hypertension, as evidenced by any of the following criteria (occurring in spite of using common criteria for prophylactic treatment and therapy):
- •History of variceal haemorrhage in past 2 years
- •History of hepatic encephalopathy
- •Platelets < 50.000 /ml
- •WBC < 3.000 / ml
- •Previous TIPSS procedure
- •Portal vein occlusion or hepatofugal flow.
- •Impaired liver function
- •Total serum bilirubin > 2.0 mg / dL
- •Serum albumin < 3.0 g /dl
- •creatinine > 2 mg / dL
- •Chemotherapy or other experimental therapy within preceding 4 weeks
- •Previous TAE / TACE
- •Previous radiation therapy to liver or lungs
- •Contraindications for angiography (severe peripheral vascular disease or uncorrectable bleeding diathesis)
- •Anatomical variants apparent on 99mTc-MAA scan precluding safe administration of RE
- •Any decompensated concomitant disease
- •Female patients who are pregnant, breast-feeding, or pre-menopausal and not practising efficient contraceptive method (hormonal contraceptive, intra-uterine device)
研究组 & 干预措施
RE
Experimental
Device: Radioembolisation with yttrium-90 labelled SIR-Spheres microspheres
干预措施: Radioembolisation (SIR-Spheres® microspheres) (Device)
TACE
Active Comparator
Transarterial Chemoembolisation with embolising agent Embospheres and chemotherapeutic agent epirubicin
干预措施: Transarterial Chemoembolisation (Drug)
结局指标
主要结局
Health-related quality of life (HRQL)
时间窗: 9 months
次要结局
- Progression Free Survival (PFS); calculated from the date of first treatment(From the date of first treatment until disease progression)
- Morphological tumour response; assessed using RESIST criteria(From the date of first treatment until disease progression)
- Functional tumour response; assessed via tumour marker reduction(From the date of first treatment until disease progression)
- Survival at 6 and 12 months(6 and 12 months from the date of first treatment)
- Overall survival(From the date of first treatment until death)
- Incidence rate of portal vein invasion(From the date of first treatment until disease progression)
- Incidence rate of extra-hepatic disease(From the date of first treatment until disease progression)
- Pharmaco-economic assessment(9 months)
研究者
研究点 (2)
Loading locations...
相似试验
进行中（未招募）
不适用
Radioembolization for HCC Patients With Personalized Yttrium-90 Dosimetry for Curative Intent (RAPY90D)Stage III Hepatocellular Carcinoma AJCC v8Stage IIIA Hepatocellular Carcinoma AJCC v8Stage IIIB Hepatocellular Carcinoma AJCC v8Stage IV Hepatocellular Carcinoma AJCC v8Stage IVA Hepatocellular Carcinoma AJCC v8Stage IVB Hepatocellular Carcinoma AJCC v8Unresectable Hepatocellular CarcinomaNCT03896646M.D. Anderson Cancer Center42
招募中
2 期
Y-90 SIRT for Unresectable HCC Larger Than 7cmHepatocellular Carcinoma Non-ResectableNCT06707233Second Affiliated Hospital of Guangzhou Medical University33
Unknown
不适用
Clinical Trial of Radiotherapy in Treating Primary Hepatocellular CarcinomaPrimary Hepatocellular CarcinomaNCT03614546The Third Xiangya Hospital of Central South University200
Unknown
不适用
REgistry of Selective Internal Radiation Therapy in TaiwaN (RESIN)Hepatocellular CarcinomaNCT03292991Taipei Veterans General Hospital, Taiwan100
Unknown
不适用
HBV-host cfDNA as Minimal Residual Tumor Marker for HBV-related HCCCarcinoma, HepatocellularNCT03020342National Taiwan University Hospital50